Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCOAST: Timing of Prasugrel in NSTEMI Patients Undergoing PCI
2009-014176-22Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prasugrel in Non-ST-segment elevation myocardial infarction (NSTEMI) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Composite cardiovascular efficacy endpoint. Started Aug 2009; status: completed.
02
Drugs
prasugrel
03
Conditions
Non-ST-segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on 2009-014176-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014176-22.